• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BMRN
Held by 2 Gurus
Share

BioMarin Pharmaceutical Inc. Stocks

$ 59.46Last Updated 28.09.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

$ 11.65B

$ 59.46
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.1%

Change

+0.01%

Fund

Bridgewater Associates

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

-0.03%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.1%+0.01%
Kenneth GriffinCITADEL ADVISORS LLC0.0%-0.03%

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

BioMarin Pharmaceutical Inc. operates as a leading biopharmaceutical firm, concentrating on the creation and worldwide commercialization of therapeutic interventions for critical, rare medical conditions and life-threatening diseases. Its market reach extends across the United States, Europe, Latin America, the Middle East, and the Asia Pacific region. The company's current portfolio features several key medications: VIMIZIM, an enzyme replacement therapy for mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder. VOXZOGO, a once-daily injectable analog of c-type natriuretic peptide (CNP), approved for achondroplasia. NAGLAZYME, a recombinant form of N-acetylgalactosamine 4-sulfatase, prescribed for patients with MPS VI. PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme, delivered subcutaneously to lower blood Phe levels. BRINEURA, a recombinant human tripeptidyl peptidase 1, indicated for ceroid lipofuscinosis type 2, a type of Batten disease. ALDURAZYME, a purified protein designed to replicate the naturally occurring human enzyme alpha-L-iduronidase. KUVAN, a proprietary synthetic oral variant of 6R-BH4, employed to manage phenylketonuria, an inherited metabolic illness. ROCTAVIAN, an adeno-associated virus (AAV) vector-based treatment for severe hemophilia A. Beyond its marketed products, BioMarin maintains an active development pipeline. This includes BMN 333, a longer-acting CNP aimed at various growth disorders like achondroplasia and hypochondroplasia; BMN 349, an experimental oral therapeutic for liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide under investigation for Duchenne muscular dystrophy. The company's distribution channels encompass specialty pharmacies, hospitals, non-U.S. government entities, distributors, and pharmaceutical wholesalers. BioMarin also holds licensing and collaborative agreements with partners such as Catalyst Pharmaceutical Partners, Inc. and Ares Trading S.A. Established in 1996, the company's corporate headquarters are located in San Rafael, California.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of BMRN is 96.1 and suggests 61.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.09.2026 16:15

The Crisis in the Strait of Hormuz and Routes to China: How to Invest in a Changing Transportation Market

29.09.2026 16:00

Morning in New York: Stocks Remain Volatile

29.09.2026 15:40

Burry increased his stake in the mid-cap retailer Sprouts. Should you follow his lead?

29.09.2026 15:20

The maker of Zuckerberg's "favorite" smart rings has postponed its IPO due to "uncertainty"

29.09.2026 14:39

Morgan Stanley has identified 12 stocks with growth potential of 40% or more amid an AI computing capacity shortage

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026